View Older Stories View More Recent Stories

Aug 25, 2020 08:00AM Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020
Aug 14, 2020 04:05PM AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 6, 2020 04:05PM Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs
Jul 30, 2020 08:00AM Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020
Jul 6, 2020 08:00AM Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority
Jun 25, 2020 08:03AM Lineage Cell Therapeutics (LCTX) Reports Update on OPC1 Cell Therapy Program for Spinal Cord Injury
Jun 25, 2020 08:00AM Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury
Jun 24, 2020 08:00AM Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
Jun 18, 2020 08:00AM Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy
Jun 17, 2020 08:00AM Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference
Jun 16, 2020 08:07AM AgeX Therapeutics Inc. (AGE), Pluristyx Announce Pact to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
Jun 16, 2020 08:00AM AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
Jun 11, 2020 08:00AM Lineage Cell Therapeutics to Present at 2020 Raymond James Human Health Innovation Conference on June 18, 2020
Jun 8, 2020 08:00AM Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen® in Dry AMD with Geographic Atrophy  
Jun 5, 2020 04:16PM AgeX Therapeutics Inc. (AGE) Receives Stock Exchange Deficiency Letter
Jun 5, 2020 04:15PM AgeX Therapeutics Receives Stock Exchange Deficiency Letter
Jun 2, 2020 08:09AM AgeX Therapeutics Inc. (AGE), ImStem Biotechnology Sign Non-Binding LOI Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
Jun 2, 2020 08:00AM AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
Jun 1, 2020 08:09AM Lineage Cell Therapeutics (LCTX) Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy
Jun 1, 2020 08:00AM Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy
May 29, 2020 08:00AM AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A
May 21, 2020 08:30AM AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer
May 19, 2020 08:00AM Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020
May 18, 2020 08:00AM Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020
May 14, 2020 04:05PM AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020 04:05PM Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020 08:00AM Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
May 6, 2020 09:07AM Lineage Cell Therapeutics (LCTX) Reports New Data With OpRegen for Treatment of Dry AMD With Geographic Atrophy
May 6, 2020 09:05AM Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy
May 5, 2020 08:00AM Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development
May 1, 2020 08:54AM AgeX Therapeutics Announces Reduction in Projected Cash Expenditures
Apr 29, 2020 08:00AM Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020
Apr 24, 2020 08:00AM Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
Mar 30, 2020 05:40PM AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update
Mar 20, 2020 09:02AM AgeX Therapeutics (AGE) Licensee ImStem Biotechnology Announces FDA has Lifted Hold and Cleared Investigational NDA for IMS001 for Treatment of MS
Mar 20, 2020 09:00AM AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
Mar 12, 2020 04:05PM Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Mar 5, 2020 08:00AM Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020
Feb 20, 2020 08:00AM Lineage Cell Therapeutics to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
Feb 18, 2020 08:00AM Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)
Feb 10, 2020 08:00AM Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference
Feb 6, 2020 08:22AM Lineage Cell Therapeutics (LCTX) Positives Update on Phase I/IIa Clinical Study of OpRegen for Treatment of Dry Age-Related Macular Degeneration
Feb 6, 2020 08:00AM Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration
Jan 2, 2020 08:00PM Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
Dec 30, 2019 08:04AM Lineage Cell Therapeutics (LCTX) Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry Age-Related Macular Degeneration
Dec 30, 2019 08:00AM Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration
Dec 24, 2019 08:02AM Lineage Cell Therapeutics (LCTX) Enters Three Separate License Agreements for IP and Assets
Dec 24, 2019 08:00AM Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets
Dec 19, 2019 08:13AM Lineage Cell Therapeutics (LCTX) Provides Shareholder Update
Dec 19, 2019 08:00AM Lineage Cell Therapeutics Provides Shareholder Update
View More Recent Stories View Older Stories